- Home
- Companies
- Theragenics
- Products
- Cesium Blu - Loose Seeds
Cesium Blu - Loose Seeds
Isoray’s Cesium Blu seeds are powered by the next-generation, brachytherapy isotope Cesium-131. The titanium cased seed contains a gold wire for visualization and affords greater flexibility of dose placement in situ, compared to stranded seed products. Loose seeds are shipped in glass vials contained within a lead pig and can be shipped in quantities of 1 to 100 seeds per vial at the specific activity requested by the customer.
- 9.7 day half-life
- Energy level at 30.4 Kev
- Faster dose delivery rate. 90% of dose delivered in ~33 days
- Detectable in the body for only 97 days
- Gold radiopaque marker
- Biocompatible Titanium casing
- 100% assay ensures accurate activity level upon implant
- Expert Sales and Support teams ensuring real-time ordering and delivery for procedures throughout the body.
- Committed to offering interactive training programs throughout the US teaching the leading techniques and the newest tools.
- Empowering patients to make their own treatment decisions based on decades of data.
Higher Energy
Isoray’s proprietary isotope, Cesium Blu, has a higher energy allowing for a more uniform dose distribution with less overdosing than other permanent isotopes.
Shorter Half-Life
Isoray’s proprietary isotope, Cesium Blu, has a shorter half-life than other commonly used isotopes for the treatment of cancer throughout the body, resulting in a shorter duration of radiation which contributes to a rapid resolution of patient side effects.
Improved Coverage of the Prostate
Isoray’s Cesium Blu proprietary permanent prostate cancer brachytherapy seeds allow for better dose homogeneity and the sparing of the urethra and rectum while providing comparable prostate coverage compared to other seeds with comparable or fewer seeds and needles.
Rapid Resolution of Side effects
Isoray’s proprietary isotope, Cesium Blu, has a shorter half-life than other commonly used isotopes for the treatment of cancer throughout the body, resulting in a shorter duration of radiation which contributes to a rapid resolution of patient side effects.
Higher Biologically Effective Dose
Isoray’s Cesium Blu also delivers a higher “biological effective dose” or BED compared to I-125 or Pd-103 across a wide range of tumor types.
PSA Control
Isoray along with investigators tracking PSA in both single arm and randomized prostate cancer treatment trials have concluded that Cesium Blu’s PSA response rates have similar early tumor control to I-125, which was previously considered the gold standard in permanent seed brachytherapy.